

INDEPENDENT LIMITED ASSURANCE STATEMENT



To: The Stakeholders of AstraZeneca Plc

Introduction and objectives of work

Bureau Veritas UK Limited (Bureau Veritas) has been engaged by AstraZeneca Plc (AstraZeneca) to provide limited assurance over sustainability activities reported in its 2016 Annual Report and form 20-F. This Assurance Statement applies to the related information included within the scope of work described below.

Selected information

The scope of our work was limited to assurance over the information included within the following sections of the Sustainability extract of 2016 Annual Report and form 20-F ('the Report') for the period 1st of January to the 31st of December 2016 (the 'Selected Information'):

- Sustainability
- Refreshed sustainability strategy
- Sustainability framework
- Benchmarking and assurance
- Safety, Health and Environment strategy
- Responsible research
- Patient safety
- Clinical trials and transparency
- Research use of human biological samples
- Animal research
- Investing for the future: Healthy Heart Africa
- Pricing and access to healthcare
- Sales and marketing ethics
- Transparency reporting
- Working with suppliers
- Safety, health and wellbeing
- Community investment
- Young Health Programme
- Disaster relief
- Develop a strong and diverse pipeline of leaders
- Human rights
- Gender diversity
- Managing change
- Employee relations
- Natural resource efficiency
- Investing for the future: Following the science to protect the environment
- Sustainability: supplementary information
- Carbon reporting

Limitations and Exclusions

Excluded from the scope of our work is any verification of information relating to:

- Activities outside the defined verification period;
- Positional statements (expressions of opinion, belief, aim or future intention by AstraZeneca) and statements of future commitment;
- Drive a vibrant, high-performing culture;
- Generate a passion for people development;
- Scope 3 greenhouse gas emissions except those related to upstream emissions from personal air travel, goods transport, downstream emissions from HFA propellants released during patient use of AstraZeneca's inhaled medicines;
- Operational carbon footprint.

This limited assurance engagement relies on a risk based selected sample of sustainability data and the associated limitations that this entails. This independent statement should not be relied upon to detect all errors, omissions or misstatements that may exist.

Responsibilities

This preparation and presentation of the Selected Information in the Report are the sole responsibility of the management of AstraZeneca.

Bureau Veritas was not involved in the drafting of the Report or of the Reporting Criteria. Our responsibilities were to:

- obtain limited assurance about whether the Selected Information has been prepared in accordance with the Reporting Criteria;
- form an independent conclusion based on the assurance procedures performed and evidence obtained; and
- report our conclusions to the Directors of AstraZeneca.

Assessment Standard

We performed our work in accordance with International Standard on Assurance Engagements (ISAE) 3000 Revised, Assurance Engagements Other than Audits or Reviews of Historical Financial Information (effective for assurance reports dated on or after December 15, 2015), and in accordance with International Standard on Assurance Engagements 3410 - 'Assurance Engagements on Greenhouse Gas Statements' ('ISAE 3410'), issued by the International Auditing and Assurance Standards Board.

Summary of work performed

As part of its independent verification, Bureau Veritas undertook the following activities:

1. Assessed the appropriateness of the Reporting Criteria for the Selected Information;
2. Conducted interviews with 23 relevant personnel of AstraZeneca;
3. Reviewed the data collection and consolidation processes used to compile the Selected Information, including assessing assumptions made, the data scope and reporting boundaries;
4. Reviewed documentary evidence provided by AstraZeneca;
5. Agreed a selection of the Selected Information to the corresponding source documentation: and
6. Reviewed the current sustainability issues that could affect AstraZeneca and are of interest to stakeholders.

Conclusion

On the basis of our methodology and the activities described above, nothing has come to our attention to indicate that the Selected Information has not been properly prepared, in all material respects, in accordance with the Reporting Criteria

Statement of Independence, Integrity and Competence

Bureau Veritas is an independent professional services company that specialises in quality, environmental, health, safety and social accountability with over 185 years history. Its assurance team has extensive experience in conducting verification over environmental, social, ethical and health and safety information, systems and processes.

Bureau Veritas operates a certified¹ Quality Management System which complies with the requirements of ISO 9001:2008, and accordingly maintains a comprehensive system of

¹ Certificate of Registration FS 34143 issued by BSI Assurance UK Limited

quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Bureau Veritas has implemented and applies a Code of Ethics, which meets the requirements of the International Federation of Inspections Agencies (IFIA)² across the business to ensure that its employees maintain integrity, objectivity, professional competence and due care, confidentiality, professional behaviour and high ethical standards in their day-to-day business activities.

The assurance team for this work does not have any involvement in any other Bureau Veritas projects with AstraZeneca.

Bureau Veritas UK Limited
London
20 February 2017



² International Federation of Inspection Agencies – Compliance Code – Third Edition